Publications of Olivier BOUCHAIN
Bookmark and Share    
Full Text
See detailWeekly cisplatin with radiotherapy for locally advanced head and neck squamous cell carcinoma.
SAUTOIS, Brieuc ULiege; SCHROEDER, Hélène ULiege; MARTIN, Marie ULiege et al

in Journal of Balkan Union of Oncology (2016), 21(4), 979-988

Background Although commonly used for the treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) concomitant radio-chemotherapy (RT-CT) with weekly cisplatin has not been definitely ... [more ▼]

Background Although commonly used for the treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) concomitant radio-chemotherapy (RT-CT) with weekly cisplatin has not been definitely studied. We conducted a single centre retrospective study with the aim to evaluate efficacy and acute toxicity of definitive concomitant RT-CT with 40 mg/m² weekly cisplatin in patients with locally advanced HNSCC with a particular emphasis on radiotherapy modality (conventional or accelerated) and dose of cisplatin delivered. Method One hundred and twelve consecutive patients were included. They were given cisplatin 40 mg/m²/week concomitantly with conventionally fractionated (CFRT) (N = 33) or accelerated (ART) (N = 79) radiotherapy. Results Radiotherapy was delivered according to the treatment plan in 104 patients and full dose was given to 107 patients. A median cumulative cisplatin dose of 240 mg/m² was delivered to patients treated with CFRT and of 200 mg/m² to those treated with ART. Overall complete response rate was 81.3%. With a median follow up of 38.4 months, median overall survival was 75 months, not influenced by radiotherapy type or cisplatin dose received. The most clinically significant grade 3 or 4 acute toxicities were stomatitis (35.7%), neutropenia (25%), anemia (12.5%) and acute kidney injury (5.4%). Conclusion Our study shows that a median cumulative dose of 200 mg/m² cisplatin can be safely delivered using a weekly regimen to patients treated with concomitant radiotherapy (CFRT or ART). Efficacy results and toxicity compare favourably with those described with triweekly cisplatin RT-CT suggesting that a randomized comparison should be undertaken. [less ▲]

Detailed reference viewed: 125 (14 ULiège)